Company Filing History:
Years Active: 2016-2017
Title: Innovations by Daniel Rowe Duncan
Introduction
Daniel Rowe Duncan is an accomplished inventor based in Boston, MA. He has made significant contributions to the field of medical technology, particularly in the treatment and prevention of neointimal stenosis. With a total of 2 patents to his name, Duncan's work is paving the way for advancements in vascular health.
Latest Patents
Duncan's latest patents focus on compositions and methods for treating and preventing neointimal stenosis. These methods involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof. The goal is to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can be utilized to prevent or inhibit neointimal stenosis or restenosis, particularly after procedures such as angioplasty, vascular grafts, or stenting. Additionally, the patents describe methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also included in his innovations.
Career Highlights
Duncan is affiliated with Yale University, where he continues to engage in groundbreaking research. His work is instrumental in developing new therapeutic strategies that can significantly improve patient outcomes in vascular treatments.
Collaborations
Duncan collaborates with notable colleagues, including Christopher K Breuer and Tarek M Fahmy. Their combined expertise enhances the research and development of innovative solutions in the medical field.
Conclusion
Daniel Rowe Duncan's contributions to the field of vascular health through his patents and research at Yale University highlight his role as a leading inventor. His work is crucial in advancing medical treatments and improving patient care.